Top 5 Genomics Companies in the World

In this piece, we will take a look at the top five genomics companies in the world. For a detailed look at the genomics industry, check out Top 20 Genomics Companies in the World.

5. 10x Genomics, Inc. (NASDAQ:TXG)

Latest Market Capitalization: $4.77 billion

10x Genomics, Inc. (NASDAQ:TXG) is a backend genomics company that provides products that help with gene mapping. Deutsche Bank estimates that 80% of the firm’s revenue comes from government and university researchers, which is a major source of growth in the genomics industry.

As of Q2 2023, 30 out of the 910 hedge funds part of Insider Monkey’s database had held a stake in 10x Genomics, Inc. (NASDAQ:TXG). Catherine D. Wood’s ARK Investment Management is the biggest shareholder among these courtesy of a $173 million investment.

4. Natera, Inc. (NASDAQ:NTRA)

Latest Market Capitalization: $5.31 billion

Natera, Inc. (NASDAQ:NTRA) sells cancer screening tests, kidney gene panel tests, and other products. The firm’s second quarter earnings provided a strong set of results that saw it grow revenue by 32% annually and increase volumes by 23% indicating strong demand for its products.

After digging through 910 hedge funds for their June quarter of 2023 investments, Insider Monkey discovered that 45 were the firm’s shareholders. Natera, Inc. (NASDAQ:NTRA)’s largest hedge fund investor is Robert Pohly’s Samlyn Capital since it owns 3.5 million shares that are worth $170 million.

3. Genscript Biotech Corporation (OTCMKTS:GNNSF)

Latest Market Capitalization: $5.5 billion

Genscript Biotech Corporation (OTCMKTS:GNNSF) is one of the few international companies on our list. It is a biotechnology firm that is headquartered in Nanjing, China. The firm’s genomics division sees it as selling gene synthesis products and genomic editing materials. It expanded its presence in the biotechnology sector in August 2023 by teaming up with a biotech firm to CAR-T cell based treatments for tumors.

2. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Latest Market Capitalization: $6.7 billion

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a biotechnology company that develops treatments for several hereditary and familial diseases. The firm has several research and development collaborations within the genomics sector, through which it seeks to combine its RNA treatments with gene treatments for a customized approach.

By the end of this year’s second quarter, 27 out of the 910 hedge funds surveyed by Insider Monkey had held a stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS). Mark Lampert’s Biotechnology Value Fund / BVF Inc is the biggest shareholder among these due to its $116 million investment.

1. Illumina, Inc. (NASDAQ:ILMN)

Latest Market Capitalization: $21.8 billion

Illumina, Inc. (NASDAQ:ILMN) is a diversified backend medical products firm with a strong presence in the genomics industry through its genome sequencing and genotyping products. The firm is currently facing a bit of trouble in the European Union as it is selling a cancer test division after its bid to acquire it was struck down by regulators.

As of Q2 2023 end, 43 out of the 910 hedge funds profiled by Insider Monkey were the firm’s investors. Illumina, Inc. (NASDAQ:ILMN)’s largest hedge fund shareholder is Robert Joseph Caruso’s Select Equity Group courtesy of its $280 million stake.

Disclosure: None. You can also take a look at Top 15 Cloud Computing Companies in the World and 11 Most Profitable Biotech Stocks Today.

Follow Insider Monkey on Twitter